Mizuho raised the firm’s price target on Quest Diagnostics (DGX) to $189 from $178 and keeps an Outperform rating on the shares. The firm ...

Barclays analyst Luke Sergott maintained a Hold rating on Quest Diagnostics (DGX – Research Report) today and set a price target of $175.00.

Barclays raised their target price on Quest Diagnostics from $168.00 to $175.00 and gave the stock an “equal weight” rating in a research note on Friday, January 31st. Jefferies Financial ...

In terms of analyst outlook, Jefferies has maintained their Buy rating for Quest Diagnostics and raised their price target to $190, reflecting confidence in the company's growth prospects. The ...

Investment analysts at Leerink Partnrs dropped their Q2 2025 earnings per share (EPS) estimates for shares of Quest ...

Quest Diagnostics (NYSE:DGX) recently introduced the AD-Detect™ blood test, a significant development aimed at confirming Alzheimer's-related amyloid brain pathology. Over the last quarter, the ...

Quest Diagnostics (NYSE:DGX ... Over the last quarter, the company's stock price moved up by 4%, despite broader market declines of 12% driven by tariff-related uncertainties.

Grail shares are trading higher Wednesday after the company announced a new collaboration with Quest Diagnostics aimed at improving provider access to its Galleri multi-cancer early detection test.

During the last three months, 9 analysts shared their evaluations of Quest Diagnostics DGX, revealing diverse outlooks from bullish to bearish. In the table below, you'll find a summary of their ...

Quest Diagnostics, Inc. engages in the provision of diagnostic testing, information, and services. It operates through the Diagnostic Information Services (DIS) and All Other segments. The DIS ...